TY - JOUR
T1 - Spherical agglomerates of lactose as potential carriers for inhalation
AU - Zellnitz, Sarah
AU - Lamešić, Dejan
AU - Stranzinger, Sandra
AU - Pinto, Joana T.
AU - Planinšek, Odon
AU - Paudel, Amrit
N1 - Funding Information:
This study was funded by the Austrian COMET Programme under the auspices of the Austrian Federal Ministry of Transport, Innovation and Technology ( BMVIT ), the Austrian Federal Ministry of Economy, Family and Youth ( BMWFJ ) and the State of Styria (Styrian Funding Agency [ SFG ]). COMET is managed by the Austrian Research Promotion Agency ( FFG ). The authors would like to thank Hartmuth Schroettner and Sabrina Mertschnigg from FELMI-ZFE (Institute of Electron Microscopy and Nanoanalysis) for providing the SEM images, and Danijel Videc for supporting the spherical crystallization experiments.
Funding Information:
This study was funded by the Austrian COMET Programme under the auspices of the Austrian Federal Ministry of Transport, Innovation and Technology (BMVIT), the Austrian Federal Ministry of Economy, Family and Youth (BMWFJ) and the State of Styria (Styrian Funding Agency [SFG]). COMET is managed by the Austrian Research Promotion Agency (FFG). The authors would like to thank Hartmuth Schroettner and Sabrina Mertschnigg from FELMI-ZFE (Institute of Electron Microscopy and Nanoanalysis) for providing the SEM images, and Danijel Videc for supporting the spherical crystallization experiments.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/2
Y1 - 2021/2
N2 - We report here on spherical lactose agglomerates as potential carriers for inhalation applications. Micromeritic properties of three spherical lactose agglomerates (SA-A, SA-B, SA-C) and a standard lactose inhalation grade carrier (Lactohale 100; LH100) were evaluated and compared. Ordered mixtures with micronized salbutamol sulfate as the model active pharmaceutical ingredient (API) and lactose carriers at two drug loadings (2 wt%, 5 wt%) were prepared, and in-vitro aerosolization performance was assessed. The spherical crystallization process led to particles with tailored micromeritic properties. These had larger specific surface area and greater fine fraction < 10 µm, compared to LH100, due to their coarse morphology. Their properties were reflected in the flowability parameters, where two types of spherical agglomerates of lactose showed more cohesive behavior compared to the other lactose grades. Blend uniformity showed improved homogeneous distribution of the API at higher drug load. In-vitro aerosolization tests showed that the spherical agglomerates of lactose enhanced the dose of API, compared to LH100. SA-B and SA-C showed significantly higher fine particle fractions at low drug load compared to the others, whereas overall, the largest fine particle fraction was for SA-B at high drug load. The carrier material attributes related to particle size, specific surface area, compressibility, flowability (cohesion, flow function), and air permeability were critical for aerosolization performance.
AB - We report here on spherical lactose agglomerates as potential carriers for inhalation applications. Micromeritic properties of three spherical lactose agglomerates (SA-A, SA-B, SA-C) and a standard lactose inhalation grade carrier (Lactohale 100; LH100) were evaluated and compared. Ordered mixtures with micronized salbutamol sulfate as the model active pharmaceutical ingredient (API) and lactose carriers at two drug loadings (2 wt%, 5 wt%) were prepared, and in-vitro aerosolization performance was assessed. The spherical crystallization process led to particles with tailored micromeritic properties. These had larger specific surface area and greater fine fraction < 10 µm, compared to LH100, due to their coarse morphology. Their properties were reflected in the flowability parameters, where two types of spherical agglomerates of lactose showed more cohesive behavior compared to the other lactose grades. Blend uniformity showed improved homogeneous distribution of the API at higher drug load. In-vitro aerosolization tests showed that the spherical agglomerates of lactose enhanced the dose of API, compared to LH100. SA-B and SA-C showed significantly higher fine particle fractions at low drug load compared to the others, whereas overall, the largest fine particle fraction was for SA-B at high drug load. The carrier material attributes related to particle size, specific surface area, compressibility, flowability (cohesion, flow function), and air permeability were critical for aerosolization performance.
KW - Dry powder inhaler
KW - Fine particle fraction
KW - Inhalation
KW - Lactose
KW - Spherical agglomerates
UR - http://www.scopus.com/inward/record.url?scp=85098214913&partnerID=8YFLogxK
U2 - 10.1016/j.ejpb.2020.12.015
DO - 10.1016/j.ejpb.2020.12.015
M3 - Article
C2 - 33358941
AN - SCOPUS:85098214913
SN - 0939-6411
VL - 159
SP - 11
EP - 20
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
ER -